Brokerages expect Auris Medical Holding AG (NASDAQ:EARS) to post ($0.22) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Auris Medical Holding AG’s earnings. Auris Medical Holding AG reported earnings per share of ($0.26) during the same quarter last year, which would suggest a positive year over year growth rate of 15.4%. The business is expected to announce its next quarterly earnings results before the market opens on Thursday, August 10th.

On average, analysts expect that Auris Medical Holding AG will report full-year earnings of ($0.74) per share for the current year. For the next fiscal year, analysts forecast that the firm will post earnings of ($0.31) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that follow Auris Medical Holding AG.

Auris Medical Holding AG (NASDAQ:EARS) last released its earnings results on Thursday, May 11th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.08.

A number of research firms recently weighed in on EARS. Roth Capital restated a “buy” rating and set a $5.00 target price on shares of Auris Medical Holding AG in a research note on Saturday, July 1st. ValuEngine downgraded Auris Medical Holding AG from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $3.42.

A number of institutional investors have recently made changes to their positions in EARS. UBS Oconnor LLC acquired a new position in shares of Auris Medical Holding AG during the first quarter worth about $909,000. Perceptive Advisors LLC acquired a new position in shares of Auris Medical Holding AG during the first quarter worth about $368,000. Sabby Management LLC acquired a new position in shares of Auris Medical Holding AG during the first quarter worth about $133,000. Finally, Sofinnova Management VIII L.L.C. increased its position in shares of Auris Medical Holding AG by 34.4% in the first quarter. Sofinnova Management VIII L.L.C. now owns 7,818,175 shares of the biotechnology company’s stock worth $7,193,000 after buying an additional 2,000,000 shares during the period. 29.05% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate Auris Medical Holding AG (EARS) Will Announce Earnings of -$0.22 Per Share” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at

Auris Medical Holding AG (EARS) traded up 0.751% during mid-day trading on Monday, reaching $0.805. 106,000 shares of the company were exchanged. The firm’s market capitalization is $35.68 million. The stock has a 50-day moving average of $0.78 and a 200 day moving average of $0.83. Auris Medical Holding AG has a 1-year low of $0.60 and a 1-year high of $5.45.

Auris Medical Holding AG Company Profile

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get a free copy of the Zacks research report on Auris Medical Holding AG (EARS)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Auris Medical Holding AG (NASDAQ:EARS)

Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with's FREE daily email newsletter.